CN118078795A - Use of isoeugenol acetate in preparation of medicine for preventing and/or treating inflammatory bowel disease - Google Patents
Use of isoeugenol acetate in preparation of medicine for preventing and/or treating inflammatory bowel disease Download PDFInfo
- Publication number
- CN118078795A CN118078795A CN202410222224.0A CN202410222224A CN118078795A CN 118078795 A CN118078795 A CN 118078795A CN 202410222224 A CN202410222224 A CN 202410222224A CN 118078795 A CN118078795 A CN 118078795A
- Authority
- CN
- China
- Prior art keywords
- inflammatory bowel
- bowel disease
- medicament
- isoeugenol acetate
- isoeugenol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000022559 Inflammatory bowel disease Diseases 0.000 title claims abstract description 43
- IUSBVFZKQJGVEP-SNAWJCMRSA-N isoeugenol acetate Chemical compound COC1=CC(\C=C\C)=CC=C1OC(C)=O IUSBVFZKQJGVEP-SNAWJCMRSA-N 0.000 title claims abstract description 37
- IUSBVFZKQJGVEP-UHFFFAOYSA-N trans-isoeugenol acetate Natural products COC1=CC(C=CC)=CC=C1OC(C)=O IUSBVFZKQJGVEP-UHFFFAOYSA-N 0.000 title claims abstract description 37
- 239000003814 drug Substances 0.000 title claims abstract description 32
- 208000024891 symptom Diseases 0.000 claims abstract description 11
- 208000035861 hematochezia Diseases 0.000 claims abstract description 8
- 206010012735 Diarrhoea Diseases 0.000 claims abstract description 6
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 claims abstract description 6
- 229920003045 dextran sodium sulfate Polymers 0.000 claims description 13
- 239000002552 dosage form Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 4
- 208000011231 Crohn disease Diseases 0.000 claims description 4
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 210000004347 intestinal mucosa Anatomy 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract description 4
- 238000011160 research Methods 0.000 abstract description 3
- 241000699670 Mus sp. Species 0.000 description 23
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 11
- 210000001072 colon Anatomy 0.000 description 7
- 230000002550 fecal effect Effects 0.000 description 6
- 210000000436 anus Anatomy 0.000 description 5
- 206010009887 colitis Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000002285 corn oil Substances 0.000 description 4
- 235000005687 corn oil Nutrition 0.000 description 4
- 230000009266 disease activity Effects 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 239000003124 biologic agent Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000001794 hormone therapy Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 1
- 244000223014 Syzygium aromaticum Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 238000012321 colectomy Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000013230 female C57BL/6J mice Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000005027 intestinal barrier Anatomy 0.000 description 1
- 230000004673 intestinal mucosal barrier function Effects 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
- 229960004963 mesalazine Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to the technical field of biological medicines, and discloses application of isoeugenol acetate in preparation of a medicine for preventing and/or treating inflammatory bowel disease. The invention provides the isoeugenol acetate as a natural medicine for preventing and/or treating inflammatory bowel disease for the first time. Experimental research shows that isoeugenol acetate can significantly improve the related symptoms of inflammatory bowel disease, especially diarrhea and hematochezia symptoms caused by inflammatory bowel disease, and has good application prospect.
Description
Technical Field
The invention relates to the technical field of biological medicines, in particular to application of isoeugenol acetate in preparing medicines for preventing and/or treating inflammatory bowel diseases.
Background
Inflammatory Bowel Disease (IBD) is a group of chronic, non-specific intestinal inflammatory diseases, mainly including both Ulcerative Colitis (UC) and Crohn's Disease (CD) disease types. In IBD patients, about 10% -30% of the clinical course appears to be progressively worse, with a cumulative risk of relapse of 70% -80% over 10 years, and thus treatment of IBD is challenging.
Glucocorticoids are first line therapeutic agents in patients with severe IBD and are one of the alternative advanced therapeutic agents in patients with light and moderate IBD who are intolerant or poorly effective to 5-ASA drugs. However, some patients with IBD show hormone therapy inefficiency or hormone dependence, resulting in poor efficacy of glucocorticoid, and some patients develop hormone-related side effects such as infection, abnormal glucose tolerance, osteoporosis, etc. during hormone therapy.
The presence of biological agents significantly improves prognosis for IBD patients, but a higher proportion of patients show primary or secondary unresponsiveness to biological agents. Studies have shown that 15% -20% of IBD patients still need colectomy treatment. The pathogenesis of IBD includes disruption of the intestinal mucosal barrier accompanied by activation of various intestinal inflammatory pathways, and thus single targeted therapies of biological agents are still insufficient to fully control intestinal inflammation.
Therefore, there is still a need to improve the therapeutic effect of related therapeutic drugs on IBD, and development of new, safe and effective therapeutic drugs for IBD treatment is still urgent.
Disclosure of Invention
The application aims to provide a novel medicament for preventing and/or treating inflammatory bowel disease. According to the application, through experiments, the isoeugenol acetate can obviously improve the related symptoms of inflammatory bowel disease, especially diarrhea and hematochezia symptoms caused by inflammatory bowel disease, and has good application prospect.
In order to achieve the aim of the application, the application adopts the following technical scheme: there is provided the use of isoeugenol acetate in the manufacture of a medicament for the prevention and/or treatment of inflammatory bowel disease.
In an alternative embodiment, the use comprises use in the manufacture of a medicament for ameliorating the symptoms of diarrhea caused by inflammatory bowel disease.
In an alternative embodiment, the use comprises use in the manufacture of a medicament for ameliorating a symptom of hematochezia caused by inflammatory bowel disease.
In an alternative embodiment, the use comprises use in the manufacture of a medicament for protecting intestinal mucosa.
In an alternative embodiment, the inflammatory bowel disease includes ulcerative colitis and crohn's disease.
In an alternative embodiment, the inflammatory bowel disease comprises inflammatory bowel disease caused by dextran sodium sulfate.
In an alternative embodiment, the medicament comprises an effective amount of isoeugenol acetate and a pharmaceutically acceptable carrier.
In an alternative embodiment, the dosage form of the medicament comprises at least one of a pill, capsule, tablet, powder, or granule.
In a second aspect, the present invention also provides a medicament for preventing and/or treating inflammatory bowel disease, the medicament comprising an effective amount of isoeugenol acetate and a pharmaceutically acceptable carrier. The medicament can be prepared into a proper dosage form by a conventional method in the field.
In an alternative embodiment, the dosage form of the medicament comprises at least one of a pill, capsule, tablet, powder, or granule.
In an alternative embodiment, the medicament comprises isoeugenol acetate as the sole active ingredient.
Isoeugenol acetate (Isoeugenol acetate) is commonly found in fragrances such as clove, cinnamon, and the like, and is commonly used in the food and cosmetic industries. The prior researches report that isoeugenol acetate has certain anti-tumor, antibacterial and antioxidant effects, but the effects of isoeugenol acetate in preventing or treating inflammatory bowel diseases are not reported yet.
Wherein, the structural formula of the isoeugenol acetate is as follows:
The etiology and pathogenesis of inflammatory bowel disease are not completely clear, and partial patients can not realize symptom improvement and mucous membrane healing by using the existing treatment mode, and adverse reaction is larger. The invention provides the isoeugenol acetate as a natural medicine for preventing and/or treating inflammatory bowel disease for the first time. Experimental research shows that isoeugenol acetate can significantly improve the related symptoms of inflammatory bowel disease, especially diarrhea and hematochezia symptoms caused by inflammatory bowel disease, and has good application prospect.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings that are needed in the description of the embodiments or the prior art will be briefly described, and it is obvious that the drawings in the description below are some embodiments of the present invention, and other drawings can be obtained according to the drawings without inventive effort for a person skilled in the art.
FIG. 1 is a graph showing the weight of each group of mice in the examples of the present invention as a function of time;
FIG. 2 is a graph showing the time dependence of the colitis Disease Activity Index (DAI) score for each group of mice in the examples of the present invention;
FIG. 3 is a photograph of colon length of each group of mice in the examples of the present invention;
FIG. 4 is a graph showing the statistical results of colon length of each group of mice in the examples of the present invention.
Detailed Description
In order to further describe the technical means and results adopted by the present invention to achieve the intended purpose, the following detailed description of the specific implementation, technical scheme and features according to the present invention will be given in the following preferred embodiments. The particular features, structures, or characteristics of the various embodiments in the description below may be combined in any suitable manner.
The specific experimental procedures or conditions are not noted in the examples and may be followed by the operations or conditions of conventional experimental procedures described in the literature in this field. The reagents or apparatus used were conventional reagent products commercially available without the manufacturer's knowledge.
The invention is described in further detail below in connection with specific examples which are not to be construed as limiting the scope of the invention as claimed.
Examples
This example was used to verify the therapeutic effect of isoeugenol acetate on inflammatory bowel disease.
(1) Experimental animals: SPF grade C57BL/6 mice (female, weight 18-22 g) were purchased from Experimental animal technologies Inc. of Leishuha, beijing.
(2) Preparation of isoeugenol acetate administration suspension: the isoeugenol acetate is dissolved by using dimethyl sulfoxide (DMSO), the obtained solution is stored in a refrigerator at the temperature of minus 20 ℃, corn oil (Corn oil) is added before each use, so that the final concentration of the isoeugenol acetate is respectively 10mg/kg and 20mg/kg, wherein the concentration of the dimethyl sulfoxide (DMSO) is 3%, and the mixture is fully and uniformly mixed by shaking.
(3) Grouping animals, modeling and administration: the IBD mouse model was constructed using sodium dextran sulfate (Dextran Sulfate Sodium, DSS) induction.
Female C57BL/6J mice were randomly grouped according to body weight, and divided into a control group, a model group (DSS), an isoeugenol acetate 10mg/kg treatment group (DSS+10 mg/kg ISA), and an isoeugenol acetate 20mg/kg treatment group (DSS+20 mg/kg ISA), each group being 5.
The mice in the control group drink distilled water, while the other groups drink 3% of DSS freely to induce colonitis of the mice; meanwhile, 10mg/kg of isoeugenol acetate treatment group was given 0.1 ml/day of the above-prepared isoeugenol acetate suspension (10 mg/kg) by intraperitoneal injection, 20mg/kg of isoeugenol acetate treatment group was given 0.1 ml/day of the above-prepared isoeugenol acetate suspension (20 mg/kg) by daily intraperitoneal injection, and the control group and DSS group were given the same amount of dimethyl sulfoxide (DMSO) +corn oil (Corn oil) by intraperitoneal injection.
Mice were weighed at the same time each day, and were observed for fecal trait and fecal occult blood condition, and were scored for Disease Activity Index (DAI) (specific scoring criteria are shown in table 1), DAI = body weight score + fecal trait score + fecal occult blood condition score.
TABLE 1 Disease Activity Index (DAI) scoring criteria
| Score of | Weight loss (%) | Fecal trait | Fecal occult blood condition |
| 0 | <1 | Normal state | Negative of |
| 1 | 1-5 | Semi-formed but non-adherent anus | Cryptographic blood positivity |
| 2 | 6-10 | Loose but not adhering to anus | Blood stool with naked eyes |
| 3 | 11-20 | Loose and adherent anus | Blood stool with naked eyes and anus adhesion |
| 4 | >20 | Water sample stool | Perianal hemorrhage |
The mice were dissected 8 days after continuous administration, the whole colon (cecum distal to anus) was rounded, and the length was measured.
(4) Experimental results:
① General observations of mice: the mice in the control group have normal diet, drinking water, activity and defecation conditions, soft and bright hair and good mental state; the mice in the model group have obvious weight reduction, reduced activity, reduced eating amount, messy and matt hair, listlessness and loose stool and hematochezia, compared with the mice in the isoeugenol acetate treatment group, which have obvious weight, hair color, spirit and movement conditions better than those of the mice in the DSS model group, have dose dependency, show better treatment effect and have specific weight change shown in figure 1.
② Mouse colitis Disease Activity Index (DAI) score: compared with the mice in the control group, the DAI score of the mice in the DSS model group is gradually increased along with time and reflects the gradual aggravation of colonitis, and the DAI score of the mice in the isoeugenol acetate treatment group is obviously lower than that of the mice in the DSS model group, and has dose dependence, and the specific experimental result is shown in figure 2.
③ Colon length measurement in mice: the colon length of the mice in the DSS model group was significantly reduced compared to the mice in the control group, while the colon length of the mice in the isoeugenol acetate treated group was significantly longer than that of the mice in the model group, and the mice in the model group had dose dependency, and the specific experimental results are shown in fig. 3 and 4.
In summary, isoeugenol acetate can improve the weight loss, DAI score and colon length change of a mouse with DSS-induced colitis, which indicates that isoeugenol acetate can improve the colitis symptoms of the mouse with DSS-induced colitis and provide a more favorable pharmacodynamic basis for clinically treating IBD.
The above description is only of the preferred embodiments of the present invention; the scope of the invention is not limited in this respect. Any person skilled in the art, within the technical scope of the present disclosure, may apply to the present invention, and the technical solution and the improvement thereof are all covered by the protection scope of the present invention.
Claims (10)
1. Use of isoeugenol acetate in the manufacture of a medicament for the prevention and/or treatment of inflammatory bowel disease.
2. Use according to claim 1, characterized in that it comprises the use in the preparation of a medicament for improving the symptoms of diarrhea and/or hematochezia caused by inflammatory bowel disease.
3. The use according to claim 1, characterized in that it comprises the use in the preparation of a medicament for protecting intestinal mucosa.
4. The use according to claim 1, wherein the inflammatory bowel disease comprises ulcerative colitis and crohn's disease.
5. The use according to claim 1, wherein the inflammatory bowel disease comprises inflammatory bowel disease caused by dextran sodium sulfate.
6. The use according to claim 1, wherein the medicament comprises an effective amount of isoeugenol acetate and a pharmaceutically acceptable carrier.
7. The use of claim 6, wherein the dosage form of the medicament comprises at least one of a pill, a capsule, a tablet, a powder, or a granule.
8. A medicament for the prevention and/or treatment of inflammatory bowel disease, comprising an effective amount of isoeugenol acetate and a pharmaceutically acceptable carrier.
9. The medicament of claim 9, wherein the dosage form of the medicament comprises at least one of a pill, a capsule, a tablet, a powder, or a granule.
10. The medicament according to claim 8 or 9, characterized in that it comprises isoeugenol acetate as the only active ingredient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410222224.0A CN118078795A (en) | 2024-02-28 | 2024-02-28 | Use of isoeugenol acetate in preparation of medicine for preventing and/or treating inflammatory bowel disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410222224.0A CN118078795A (en) | 2024-02-28 | 2024-02-28 | Use of isoeugenol acetate in preparation of medicine for preventing and/or treating inflammatory bowel disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118078795A true CN118078795A (en) | 2024-05-28 |
Family
ID=91155973
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410222224.0A Pending CN118078795A (en) | 2024-02-28 | 2024-02-28 | Use of isoeugenol acetate in preparation of medicine for preventing and/or treating inflammatory bowel disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN118078795A (en) |
-
2024
- 2024-02-28 CN CN202410222224.0A patent/CN118078795A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108236608B (en) | Pharmaceutical composition of cannabidiol and vigabatrin and application thereof | |
| CA3049125C (en) | Compositions for use in treating inflammatory bowel diseases and intestinal colitis | |
| CN112638378A (en) | Composition for eradicating helicobacter pylori | |
| Qian et al. | The first clinical trial of gossypol on male antifertility | |
| CN118078795A (en) | Use of isoeugenol acetate in preparation of medicine for preventing and/or treating inflammatory bowel disease | |
| US20220323481A1 (en) | Pharmaceutical composition for treatment and prevention of chronic disease | |
| US20030207819A1 (en) | Compositions and methods for treating inflammatory connective tissue diseases | |
| Sanders | Treatment of typhoid fever: a comparative trial of ampicillin and chloramphenicol. | |
| Feagan et al. | OP17 Upadacitinib Improves Endoscopic Outcomes in Patients with Moderate to Severely Active Crohn’s Disease Irrespective of Previous Failure to Respond to Biologics or Conventional Therapies | |
| CN101530405A (en) | Citric acid and compound citric acid application in pharmacy | |
| CA2371393C (en) | Use of bismuth subgallate in inhibition of production of nitric oxide synthase | |
| US20220257727A1 (en) | Pharmaceutical composition containing lysozyme and use thereof | |
| CN102755342B (en) | Compound paracetamol injection and preparation method thereof | |
| Shiba et al. | Erythematous and bullous rash strongly indicating toxic epidermal necrolysis associated with the use of intravenous ritodrine hydrochloride | |
| NL2036449B1 (en) | Use of bacillus coagulans bc198 for improving intestinal inflammatory diseases | |
| Widjanarko et al. | Laxative potential of the konjac flour (Amorphophallus muelleri Blume) in treatment of loperamide induced constipation on Sprague Dawley rats | |
| US4346095A (en) | Therapeutic treatment for viral hepatitis infection | |
| CN109700757A (en) | A kind of Mesalazine and the compound preparation of paracetamol and application thereof | |
| CN113425713B (en) | Pharmaceutical composition for treating duodenal ulcer | |
| CN103193853A (en) | Compound and composition used for treating psoriasis, and preparation method thereof | |
| CN117224554A (en) | Application of Capelliposide A in preparation of medicines for treating ulcerative colitis | |
| CN118286224A (en) | Application of dasatinib and quercetin combination in preparation of medicines for treating ulcerative colitis | |
| Geiger et al. | Effects of Gastro-Intestinal Resections in Swine on the Anti-Anemia Potency of the Liver: With Observations on the Nature and Sources of the Materials Effective in Pernicious Anemia | |
| Seligman | Treatment of vulval candidiasis with 5-fluorocytosine. | |
| Glick | Preliminary clinical evaluation of fenclofenac (32 patients) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |